The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
The product is expected to be launched by Q4 FY23.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The company is focussed on increasing the capacity utilizations while controlling costs
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
